UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 180 filers reported holding UNIQURE NV in Q2 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,098,805 | -37.6% | 461,819 | +6.6% | 0.00% | 0.0% |
Q2 2023 | $4,967,039 | -42.5% | 433,424 | +1.0% | 0.00% | -50.0% |
Q1 2023 | $8,645,820 | -12.6% | 429,286 | -1.6% | 0.00% | 0.0% |
Q4 2022 | $9,887,656 | +12.0% | 436,156 | -7.3% | 0.00% | 0.0% |
Q3 2022 | $8,826,000 | +17.5% | 470,482 | +16.8% | 0.00% | 0.0% |
Q2 2022 | $7,511,000 | +37.3% | 402,931 | +33.1% | 0.00% | +100.0% |
Q1 2022 | $5,470,000 | -19.6% | 302,690 | -7.8% | 0.00% | 0.0% |
Q4 2021 | $6,806,000 | -63.5% | 328,157 | -43.7% | 0.00% | -75.0% |
Q3 2021 | $18,670,000 | +38.5% | 583,269 | +33.2% | 0.00% | +33.3% |
Q2 2021 | $13,483,000 | -34.0% | 437,782 | -27.9% | 0.00% | -40.0% |
Q1 2021 | $20,444,000 | +27.0% | 606,846 | +36.2% | 0.01% | +25.0% |
Q4 2020 | $16,097,000 | +5.8% | 445,545 | +7.8% | 0.00% | -20.0% |
Q3 2020 | $15,216,000 | +560.1% | 413,152 | +707.5% | 0.01% | +400.0% |
Q2 2020 | $2,305,000 | +6.4% | 51,165 | +12.0% | 0.00% | 0.0% |
Q1 2020 | $2,167,000 | -85.6% | 45,668 | -78.2% | 0.00% | -75.0% |
Q4 2019 | $15,019,000 | +598.9% | 209,578 | +283.9% | 0.00% | +300.0% |
Q3 2019 | $2,149,000 | -11.1% | 54,593 | +76.6% | 0.00% | 0.0% |
Q2 2019 | $2,416,000 | -41.5% | 30,915 | -55.4% | 0.00% | 0.0% |
Q1 2019 | $4,131,000 | +255.2% | 69,253 | +71.7% | 0.00% | – |
Q4 2018 | $1,163,000 | -30.2% | 40,342 | -11.9% | 0.00% | – |
Q3 2018 | $1,667,000 | +5.0% | 45,796 | +9.1% | 0.00% | – |
Q2 2018 | $1,587,000 | +312.2% | 41,992 | +156.3% | 0.00% | – |
Q1 2018 | $385,000 | +3.2% | 16,384 | -13.9% | 0.00% | – |
Q4 2017 | $373,000 | +372.2% | 19,037 | +39.8% | 0.00% | – |
Q1 2017 | $79,000 | -3.7% | 13,619 | -6.8% | 0.00% | – |
Q4 2016 | $82,000 | -74.5% | 14,606 | -65.2% | 0.00% | – |
Q3 2016 | $321,000 | +245.2% | 41,918 | +231.1% | 0.00% | – |
Q2 2016 | $93,000 | -88.1% | 12,661 | -73.1% | 0.00% | – |
Q4 2015 | $779,000 | -68.4% | 47,025 | -61.0% | 0.00% | -100.0% |
Q3 2015 | $2,468,000 | – | 120,710 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |